Viveve Reports Third Quarter 2018 Financial Results 


– Continued commercial growth for Viveve System including record quarter of treatment tip sales
– Significant advancement of clinical programs targeting new indications in sexual function and stress urinary incontinence (SUI)
“Viveves strong commercial growth continued in the third quarter, particularly in the U.S., as a result of our continued focus on expanding our global sales operations”, stated Scott Durbin, chief executive officer and director. Mr. Durbin added, We believe our monopolar cryogen-cooled radiofrequency (CMRF) technology platform is well positioned for …

[Read on via official release]

Source: US SEC
View full document: